Skip to content Skip to footer
Subscribe Now
Viewpoints_Salom Juethner
VIEWPOINTS

PharmaShots Interview: Takeda Salom Juethner Shares Insights on the Data Publication to Support the Sustained Safety and Efficacy of Takhzyro

In an interview with PharmaShots, Salomé Juethner, Senior Medical Director, Rare Diseases at Takeda shared her views on the P-III HELP study of Takhzyro for the prevention of hereditary angioedema attacks in the Journal Allergy Shots: The P-III HELP OLE study evaluates the safety & efficacy of Takhzyro (300mg, q2w) in 212 patients aged =12yrs. with HAE attacks for ~2.5yrs.…
October 6, 2021

Read more

Viewpoints_James E. Brown
VIEWPOINTS

PharmaShots Interview: Durect’s James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021

In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment Shots: The P-Ib trial evaluates DUR-928 (50/150/600mg for 4wks.) in 65 patients with NASH with stage 1-3 fibrosis which showed improvement…
September 20, 2021

Read more